Remove 2030 Remove Finance Remove Private Equity Firm
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales. The tailwinds So, what else can we thank for the relative resilience of M&A in the life sciences industry as we head into 2024? Multiple factors, as it turns out. billion.

article thumbnail

Saudi Arabia: The Corporate Bet

Global Finance

In the final stretch of its Vision 2030 development blueprint, Saudi Arabia is counting on FDI to play a bigger role. Initially expected to be taken up by 540 companies by 2030, the kingdom surpassed this goal within the first year. So far, most of these have been financed locally, largely with oil money.